These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34544617)

  • 1. The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2.
    Maxwell LJ; Beaton DE; Boers M; D'Agostino MA; Conaghan PG; Grosskleg S; Shea BJ; Bingham Iii CO; Boonen A; Christensen R; Choy E; Doria AS; Hill CL; Hofstetter C; Kroon FP; Leung YY; Mackie S; Meara A; Touma Z; Tugwell P; Wells GA
    Semin Arthritis Rheum; 2021 Dec; 51(6):1320-1330. PubMed ID: 34544617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.
    Beaton DE; Maxwell LJ; Shea BJ; Wells GA; Boers M; Grosskleg S; Bingham CO; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March LM; Simon LS; Singh JA; Strand V; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1028-1035. PubMed ID: 30709952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging.
    D'Agostino MA; Beaton DE; Maxwell LJ; Cembalo SM; Hoens AM; Hofstetter C; Zabalan C; Bird P; Christensen R; de Wit M; Doria AS; Maksymowych WP; Oo WM; Østergaard M; Serban T; Sloan VS; Terslev L; van Rossum MA; Conaghan PG; Boers M
    Semin Arthritis Rheum; 2021 Oct; 51(5):1125-1133. PubMed ID: 34452758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The OMERACT Stepwise Approach to Select and Develop Imaging Outcome Measurement Instruments: The Musculoskeletal Ultrasound Example.
    Terslev L; Naredo E; Keen HI; Bruyn GAW; Iagnocco A; Wakefield RJ; Conaghan PG; Maxwell LJ; Beaton DE; Boers M; D'Agostino MA
    J Rheumatol; 2019 Oct; 46(10):1394-1400. PubMed ID: 30877208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments.
    Naye F; Toupin-April K; de Wit M; LeBlanc A; Dubois O; Boonen A; Barton JL; Fraenkel L; Li LC; Stacey D; March L; Barber CEH; Hazlewood GS; Guillemin F; Bartlett SJ; Berthelsen DB; Mather K; Arnaud L; Akpabio A; Adebajo A; Schultz G; Sloan VS; Gill TK; Sharma S; Scholte-Voshaar M; Caso F; Nikiphorou E; Nasef SI; Campbell W; Meara A; Christensen R; Suarez-Almazor ME; Jull JE; Alten R; Morgan EM; El-Miedany Y; Singh JA; Burt J; Jayatilleke A; Hmamouchi I; Blanco FJ; Fernandez AP; Mackie S; Jones A; Strand V; Monti S; Stones SR; Lee RR; Nielsen SM; Evans V; Srinivasalu H; Gérard T; Demers JL; Bouchard R; Stefan T; Dugas M; Bergeron F; Beaton D; Maxwell LJ; Tugwell P; Décary S
    Semin Arthritis Rheum; 2024 Apr; 65():152344. PubMed ID: 38232625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases.
    Lyne SA; Yip K; Vasiliou VS; Katz DA; Richards P; Tieu J; Black RJ; Bridgewater S; Palmowski A; Beaton D; Maxwell LJ; Robson JC; Mackie SL; Goodman SM; Hill CL
    Semin Arthritis Rheum; 2024 Feb; 64():152338. PubMed ID: 38134623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.
    Boers M; Kirwan JR; Gossec L; Conaghan PG; D'Agostino MA; Bingham CO; Brooks PM; Landewé R; March L; Simon L; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2014 May; 41(5):1025-30. PubMed ID: 24584913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report.
    Duarte-García A; Leung YY; Coates LC; Beaton D; Christensen R; Craig ET; de Wit M; Eder L; Fallon L; FitzGerald O; Gladman DD; Goel N; Holland R; Lindsay C; Maxwell L; Mease P; Orbai AM; Shea B; Strand V; Veale DJ; Tillett W; Ogdie A
    J Rheumatol; 2019 Aug; 46(8):996-1005. PubMed ID: 30770518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process.
    Kroon FPB; van der Heijde D; Maxwell LJ; Beaton DE; Abishek A; Berenbaum F; Blanco FJ; Conaghan PG; Dziedzic K; Hill CL; Haugen IK; Ishimori M; Ritschl V; Stamm TA; Wittoek R; Kloppenburg M
    Semin Arthritis Rheum; 2021 Dec; 51(6):1311-1319. PubMed ID: 34538514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.
    Boers M; Kirwan JR; Wells G; Beaton D; Gossec L; d'Agostino MA; Conaghan PG; Bingham CO; Brooks P; Landewé R; March L; Simon LS; Singh JA; Strand V; Tugwell P
    J Clin Epidemiol; 2014 Jul; 67(7):745-53. PubMed ID: 24582946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining domains: developing consensus-based definitions for foundational domains in OMERACT core outcome sets.
    Maxwell LJ; Jones C; Bingham CO; Boers M; Boonen A; Choy E; Christensen R; Conaghan PG; D'Agostino MA; Doria AS; Grosskleg S; Hill CL; Hofstetter C; Horgan B; Kroon F; Leung YY; Mackie S; Meara A; Shea BJ; Simon LS; Touma Z; Tugwell P; Wells GA; Beaton DE
    Semin Arthritis Rheum; 2024 Jun; 66():152423. PubMed ID: 38460282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets.
    Tunis SR; Maxwell LJ; Graham ID; Shea BJ; Beaton DE; Bingham CO; Brooks P; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March LM; Simon LS; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2017 Oct; 44(10):1551-1559. PubMed ID: 28765256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.
    Maxwell LJ; Beaton DE; Shea BJ; Wells GA; Boers M; Grosskleg S; Bingham CO; Conaghan PG; D'Agostino MA; de Wit M; Gossec L; March L; Simon LS; Singh JA; Strand V; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1014-1020. PubMed ID: 30770502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Domains selection for patient-reported outcomes: current activities and options for future methods.
    Tugwell PS; Petersson IF; Boers M; Gossec L; Kirwan JR; Rader T; Sanderson TC; van de Laar MA; Ueffing E; Witter JP
    J Rheumatol; 2011 Aug; 38(8):1702-10. PubMed ID: 21807789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OMERACT Definitions for Ultrasonographic Pathologies and Elementary Lesions of Rheumatic Disorders 15 Years On.
    Bruyn GA; Iagnocco A; Naredo E; Balint PV; Gutierrez M; Hammer HB; Collado P; Filippou G; Schmidt WA; Jousse-Joulin S; Mandl P; Conaghan PG; Wakefield RJ; Keen HI; Terslev L; D'Agostino MA;
    J Rheumatol; 2019 Oct; 46(10):1388-1393. PubMed ID: 30709946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set.
    Morillon MB; Nørup A; Singh JA; Dalbeth N; Taylor WJ; Kennedy MA; Pedersen BM; Grainger R; Tugwell P; Perez-Ruiz F; Diaz-Torne C; Edwards NL; Shea B; Ellingsen TJ; Christensen R; Stamp LK;
    Semin Arthritis Rheum; 2023 Jun; 60():152191. PubMed ID: 36963128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF.
    Leung YY; Orbai AM; Hojgaard P; Holland R; Mathew AJ; Goel N; Chau J; Tillett W; Lindsay C; Ogdie A; Coates LC; Gladman DD; Christensen R; Mease P; Strand V
    Semin Arthritis Rheum; 2021 Oct; 51(5):1117-1124. PubMed ID: 34392975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Composite outcomes at OMERACT: Multi-outcome domains and composite outcome domains.
    Wells GA; Tugwell P; Tomasson G; Guillemin F; Maxwell LJ; Shea BJ; Grosskleg S; Merkel PA; March L; Beaton DE
    Semin Arthritis Rheum; 2021 Dec; 51(6):1370-1377. PubMed ID: 34863558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
    Robson JC; Tomasson G; Milman N; Ashdown S; Boonen A; Casey GC; Cronholm PF; Cuthbertson D; Dawson J; Direskeneli H; Easley E; Kermani TA; Farrar JT; Gebhart D; Lanier G; Luqmani RA; Mahr A; McAlear CA; Peck J; Shea B; Shea JA; Sreih AG; Tugwell PS; Merkel PA
    J Rheumatol; 2017 Oct; 44(10):1529-1535. PubMed ID: 28864650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.
    Orbai AM; Holland R; Leung YY; Tillett W; Goel N; Christensen R; McHugh N; Gossec L; de Wit M; Højgaard P; Coates LC; Mease PJ; Birt J; Fallon L; FitzGerald O; Ogdie A; Shea B; Strand V; Duffin KC; Tugwell P; Beaton D; Gladman DD
    J Rheumatol; 2019 Aug; 46(8):990-995. PubMed ID: 30554154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.